SCHEMBL1630707

SCHEMBL1630707

Cc1cc(C#N)ccc1-c1cn(C(C)C)c2cc(NS(C)(=O)=O)ccc12

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PGR P06401 9/20 0.76
NR3C1 P04150 7/20 0.76
NR3C2 P08235 7/20 0.76
AR P10275 6/20 0.67
SCN9A Q15858 2/20 0.47
KAT2B Q92831 1/20 0.41
BRD1 O95696 2/20 0.39
BRPF1 P55201 2/20 0.39
BRD4 O60885 2/20 0.39
TDP2 O95551 2/20 0.37
BRD9 Q9H8M2 1/20 0.37
BRD7 Q9NPI1 1/20 0.37
BRPF3 Q9ULD4 1/20 0.37
TNIK Q9UKE5 1/20 0.37
CYP17A1 P05093 1/20 0.37
IMPDH2 P12268 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632203 0.88 PGR (0.73) PGRNR3C1NR3C2ARSCN9A
SCHEMBL14472315 0.87 PGR (0.71) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630210 0.87 PGR (0.71) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1632037 0.86 PGR (1.00) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1631186 0.84 PGR (0.59) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630776 0.83 PGR (0.79) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1630991 0.83 PGR (0.74) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629481 0.83 PGR (0.69) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1629393 0.82 PGR (0.78) PGRNR3C1NR3C2ARSCN9A
SCHEMBL1632024 0.82 PGR (0.73) PGRNR3C1NR3C2ARSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
US-7932284-B2 Indole sulfonamide modulators of progesterone receptors ELI LILLY AND COMPANY (US) 2011-04-26 US disclosed
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors ELI LILLY AND COMPANY 2009-03-12 US disclosed
EP-1979314-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS Eli Lilly & Company (US) 2008-10-15 EP disclosed
WO-2007087488-A9 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2008-08-28 WO disclosed
WO-2007087488-A9 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2008-08-28 WO disclosed
WO-2007087488-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-02 WO disclosed
WO-2007087488-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors PGR, NPSR1, PRLHR PGR 1/4885NR3C1 63/4885NR3C2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.